My research interests are focused on human retinal degenerative diseases. I use electrophysiological and psychophysical tests to characterize the clinical physiology and phenotype of inherited and acquired retinal disorders; diagnosis and follow up of course of disease progression, electrophysiological assessment of therapies, development of outcome measures, conducting clinical trials, studying retinal function-structure relationships. / I also manage an animal electrophysiology lab where I characterize and study animal models of human retinal degenerative diseases. We are interested in the functional assessment of retinal function using electrophysiological techniques in rodents, evaluation of experimental treatments for human degenerative diseases, assessment of retinal function and rescue in mice that have received treatment like gene therapy; collaborative efforts in translational research, development and refinement of techniques to relate function with pathology; drug toxicity and drug efficacy studies. / I am involved in several collaborative clinical and animal studies and I offer these tests as a service. / /
Thompson DA*, Khan NW* (1*/13), Othman MI*, Swaroop A, Heckenlively JR. Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGR-ORF15. PLoS ONE. 7:e35865, 2012. PMID: 22563472.
Weizer, JS, Musch DC, Niziol LM, Khan NW. Multifocal Visual Evoked Potentials for Early Glaucoma Detection. Ophthal. Surg., Lasers & Imaging (in press).
Cheng H, Khan NW, Roger JE, Swaroop A. Excess cones in the retinal degeneration rd7 mouse, caused by the loss of function of orphan nuclear receptor Nr2e3, originate from early-born photoreceptor precursors. Hum. Mol. Genet. 20:4102-15, 2011. PMID: 21813656.
Chavali VR, Khan NW, Cukras C, Bartsch D-U, Sieving P, Jablonski MM, Ayyagari R. A CTRP5 gene S163R mutation knock-in mouse model for late-onset retinal degeneration. Hum. Mol. Genet. 20:2000-14, 2011. PMID: 21349921.
Yao J, Jia L, Khan NW, Zheng QD, Moncrief A, Hauswirth WW, Thompson DA, Zacks DN. Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: Improving efficacy and prolonging the treatment window. PLoS ONE 7:e37197, 2012. PMID: 22615940.